Home WebinarsHow to Prevent Protein Aggregation through Stabilizers and Surfactants

How to Prevent Protein Aggregation through Stabilizers and Surfactants

WEBINAR

Aggregation of therapeutic proteins can occur during all steps of drug product manufacturing and handling. One option to efficiently prevent protein aggregation in solution is the application of excipients. Depending on the underlying mechanism of protein aggregation, different classes of excipients such as stabilizers and surfactants are required to stabilize the protein. Stabilizers enhance protein stability in the bulk whereas surfactants efficiently prevent agitation- and surface-induced protein aggregation.

This webinar will provide a comprehensive overview of protein aggregation, underlying mechanisms, and stabilization techniques using (novel) excipients in parenteral formulations.

In this webinar, you will learn:

About mechanisms involved in the formation of protein particles
Why different classes of excipients are required to prevent protein aggregation
About our novel surfactants/stabilizers and their capability to overcome challenges associated with protein instability

Speakers

Michelle Pascale Zoeller

MilliporeSigma

Senior Scientist

Michelle Zoeller is a senior scientist focusing on novel modality formulation at MilliporeSigma. She has 6 years of experience in the field of parenteral formulations of proteins and novel modalities. Michelle holds an M.Sc. in biomolecular engineering from TU Darmstadt. She then participated in a joint Ph.D. program between MilliporeSigma, Heidelberg University, and the Steinbeis Transfer Center of Biopharmacy and Analysis, during which she worked on the characterization of novel surfactants for the formulation of therapeutic proteins.

Can Araman, Ph.D.

MilliporeSigma

Senior Manager, Lab Head

Can Araman is a senior manager heading the protein formulation laboratory in MilliporeSigma's process solutions department in Darmstadt, Germany. His team is working on delivering solutions to challenges in protein formulations stemming mainly from the viscosity and aggregation of proteins. Can holds a Ph.D. from the Institute of Biological Chemistry in Vienna and has had a long-lasting experience in protein biochemistry, including antibody and ADC development for pre-clinical studies and clinical trials.